Vertex Pharmaceuticals

VRTX Health Care Market cap $132B as of Sep 14, 2026 16:00 ET S&P 500

Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026

Revenue$3.33B +12% year over year

Gross profit$2.85B 85% margin

Operating profit$1.25B 37% margin

Net profit$1.10B 33% margin

The numbers behind the diagram

All figures in billions of U.S. dollars, for Q2 FY26 (period ends Jun 30, 2026).
Item	Value	Share of revenue	Year over year
Revenue	3.33	100%	+12%
Trikafta/Kaftrio	2.50	75%	−2%
Alyftrek	0.57	17%	+266%
Manufactured product other	0.14	4%
Casgevy	0.08	2%
Journavx	0.05	2%
Cost of revenue	−0.49	15%
Gross profit	2.85	85% margin	−1pp
SG&A	−0.58	17%	+3pp
Other	−1.02	31%
Operating profit	1.25	37% margin	−1pp
Other income, net	0.15
Tax	−0.29
Net profit	1.10	33% margin	−2pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
Item	Value	Share of revenue	Year over year
Revenue	2.99	100%	+8%
Trikafta/Kaftrio	2.36	79%	−7%
Alyftrek	0.42	14%	+687%
Manufactured product other	0.14	5%	−12%
Casgevy	0.04	1%	+202%
Journavx	0.03	1%
Cost of revenue	−0.39	13%
Gross profit	2.59	87% margin	+0pp
SG&A	−0.49	17%	+2pp
Other	−0.96	32%	+0pp
Operating profit	1.14	38% margin	+15pp
Other income, net	0.12
Tax	−0.22
Net profit	1.03	35% margin	+11pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.19	100%	+10%
Trikafta/Kaftrio	2.57	81%	−5%
Alyftrek	0.38	12%
Manufactured product other	0.24	7%	+24%
Cost of revenue	−0.47	15%
Gross profit	2.72	85% margin	+0pp
SG&A	−0.49	15%	+2pp
Other	−1.03	33%	+0pp
Operating profit	1.21	38% margin	+3pp
Other income, net	0.13
Tax	−0.14
Net profit	1.19	37% margin	+6pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	3.08	100%	+11%
Trikafta/Kaftrio	2.65	86%	+3%
Alyftrek	0.25	8%
Manufactured product other	0.18	6%	−6%
Cost of revenue	−0.42	13%
Gross profit	2.66	87% margin	+1pp
SG&A	−0.45	14%	+1pp
Other	−1.03	34%	+0pp
Operating profit	1.19	39% margin	−2pp
Other income, net	0.11
Tax	−0.22
Net profit	1.08	35% margin	−3pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Filing on EDGAR This quarter on its own page

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 30, 2025).
Item	Value	Share of revenue	Year over year
Revenue	2.97	100%	+12%
Trikafta/Kaftrio	2.55	86%	+4%
Manufactured product other	0.24	8%	+20%
Alyftrek	0.16	5%
Collaborative & royalty	0.02	1%
Cost of revenue	−0.41	14%
Gross profit	2.56	86% margin	+0pp
SG&A	−0.43	14%	+0pp
Other	−0.98	33%	+0pp
Operating profit	1.15	39% margin	+172pp
Other income, net	0.13
Tax	−0.25
Net profit	1.03	35% margin	+171pp

Filing on EDGAR This quarter on its own page

Financial health

The balance sheet, the quarter's capital flow, the debt schedule and the capital structure of the quarter shown above.

Every set of results we hold, newest first. Open one on its own page.

Quarter	Period	Reported	Revenue	Year over year	Operating margin	Net profit	Net margin
Q2 FY26 Apr 1 – Jun 30, 2026 reported Aug 4, 2026 Operating margin 37% Net profit $1.10B	Apr 1 – Jun 30, 2026	Aug 4, 2026	$3.33B	+12%	37%	$1.10B	33%
Q1 FY26 Jan 1 – Mar 31, 2026 reported May 5, 2026 Operating margin 38% Net profit $1.03B	Jan 1 – Mar 31, 2026	May 5, 2026	$2.99B	+8%	38%	$1.03B	35%
Q4 FY25 Oct 1 – Dec 31, 2025 reported Feb 13, 2026 Operating margin 38% Net profit $1.19B	Oct 1 – Dec 31, 2025	Feb 13, 2026	$3.19B	+10%	38%	$1.19B	37%
Q3 FY25 Jul 1 – Sep 30, 2025 reported Nov 4, 2025 Operating margin 39% Net profit $1.08B	Jul 1 – Sep 30, 2025	Nov 4, 2025	$3.08B	+11%	39%	$1.08B	35%
Q2 FY25 Apr 1 – Jun 30, 2025 reported Aug 5, 2025 Operating margin 39% Net profit $1.03B	Apr 1 – Jun 30, 2025	Aug 5, 2025	$2.97B	+12%	39%	$1.03B	35%